Protein Aggregation Inhibitors is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
Mermaid diagram (expand to render)
Protein aggregation inhibitors are small molecules and biological agents designed to prevent or reverse the pathological accumulation of misfolded proteins in neurodegenerative diseases. These therapies target the fundamental process underlying disorders like Alzheimer's disease ([Abeta](/proteins/amyloid-beta), tau), Parkinson's disease (alpha-synuclein), Huntington's disease (mutant [huntingtin](/proteins/huntingtin-protein)), ALS (SOD1, TDP-43), and prion diseases. aggregation Several inhibitors have reached clinical trials, with some showing promise in modifying disease progression. [@wischik2019]
Molecular Mechanism
Aggregation inhibitors work through multiple mechanisms: [@levin2022]
The study of Protein Aggregation Inhibitors has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Allen Brain Atlas Resources
[Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
[Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury
References
[Eisenberg DS, et al, Towards the design of anti-aggregation drugs (2023)](https://pubmed.ncbi.nlm.nih.gov/37653128/)
[Wischik CM, et al, Tau aggregation inhibitor therapy for Alzheimer's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31722013/)
[Levin J, et al, The oligomer modulator anle138b in Parkinson's disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35694922/)
[Bieschke J, et al, EGCG remodels mature α-synuclein and amyloid-β fibrils (2021)](https://pubmed.ncbi.nlm.nih.gov/33827915/)
[Miller DW, et al, Targeting protein aggregation in neurodegeneration (2020)](https://pubmed.ncbi.nlm.nih.gov/32612255/)
[Schedin-Weiss S, et al, Lysosome-targeted aggregation inhibitors (2022)](https://pubmed.ncbi.nlm.nih.gov/35472312/)
[Nguyen PH, et al, Amyloid inhibitors and the nucleation-elongation model (2021)](https://pubmed.ncbi.nlm.nih.gov/33764702/)
[Sarell CJ, et al, Antisense and peptide approaches (2023)](https://pubmed.ncbi.nlm.nih.gov/37175123/)
Pathway Diagram
The following diagram shows the key molecular relationships involving Protein Aggregation Inhibitors discovered through SciDEX knowledge graph analysis: